Quincy A. Ayscue, Jr.

Successfully managed 9 Movement Disorders Centers while expanding Abbott DBS platform utilization across Mid-Atlantic region

Integrated 2 separate territories in February 2021 and managed both as solo representative

Ranked 8th- Territory Manager III of the Year 2022

Ranked 6th- Winner's Circle 2022

117% to plan Q2 2022

114% to plan Q1 2022

President's Club Trip Award Winner 2021

Top Gun Award Winner 2021

102.5% to plan FY21

138% Growth in 2021 over prior year

101% to plan December 2020

108% to plan November 2020

160% to plan October 2020

273% to plan January 2020

118% to plan December 2019

101% to plan November 2019

• Initiated nine new trialing accounts within first 6 months of 2018
• Responsible for value analysis approval of trials and implants in four new ASC locations since April 2018
• Organized two preceptorships for local pain management groups to advance technical expertise and patient selection criteria in April, May and September 2018
• Tasked with MRI reach-out program to build awareness in DC metro area for Senza and Senza II
• 169% to plan May 2018
• 338% to plan June 2018
• 122% to plan July 2018
• 167% to plan August 2018
• 427% to plan September 2018
• 209% to plan Q3 2018

• Successful launch of Prometra II Intrathecal Infusion System in Washington, D.C. and Baltimore, Md. pain and neurosurgical market
• Successfully converted all National Spine and Pain intrathecal pain pump providers in Maryland to Flowonix dominated accounts within first six months
• Solely responsible for Flowonix Prometra II value analysis approval within Trinity Healthcare system which includes 93 hospitals in 22 states
• Responsible for conducting referral events to educate the local PCP population as to the risks associated with prescribing opioids and the new CDC guidelines

• Managed Spring 2016 launch of new AlgoVita spinal cord stimulation system to Washington, DC and Baltimore, Md. market
• Enrolled 5 new pain centers to begin utilizing AlgoVita system in already mature SCS market

• Savvy at new product launches with immediate integration by skillfully negotiating contracts at both hospital and ASC level via value analysis committees
• Consultative promotion in Medtronic Therapies including spinal cord stimulation and Intrathecal targeted drug delivery for intractable pain resulting in 90% market penetration
• Collaborated with pain management, physical medicine and rehabilitation, neurology and neurosurgical practices in referral development and provide education leading to a more modern algorithm of triage for those suffering with chronic pain
• Educate and train regional attending physicians and fellows by supporting local didactic and practical cadaver events
• Promote and market for local physicians who consistently have the best outcomes by networking them with Neurology, Internal Medicine, Podiatry, Orthopedics, and Neurosurgery practices
• Train and orient newly hired Clinical Specialists and Therapy Consultants
• Full Line Therapy Consultant of Quarter Q1FY06, Q2FY06, Q3FY07, Q4FY08, Q1 FY10, Q2FY10, Q3FY10, Q4FY10, Q1FY11, Q3FY12
• Team Therapy Consultant ALL STAR Award FY06, FY10, FY12
• ALL STAR Trip Award winner FY10, FY12
• ALL STAR Award winner FY06

• Sales and service of Orthofix external fixation devices for limb-lengthening, angular correction, traumatic fracture reduction of long bones and various other orthopedic and podiatric corrective surgeries
• Supported growth of Orthofix PEMF bone stimulators for non-union and delayed union fractures and osteotomies
• Responsible for education of attending and fellow physicians on proper application and usage of external fixators resulting in best outcomes for lengthening, angular corrections and healing
• OR Territory Manager of FY2002
• Presidents Club FY2002
• Mid-Atlantic Rookie of FY 2002
• 153% to plan 2002
• 107% to Plan 2003
• Quota Buster Club 2003

• District leader for developing Grand Rounds programs for physicians, physician assistants and nurse practitioners
• Ranked number two in district in Sale of Verelan PM at 121% of goal attainment and 109% overall product line covered
• Successful in reaching all sales goals within first year
• Responsible for sales and marketing of broad spectrum of anti-hypertensive pharmaceutical products to physicians